David S. Ege - 03 Feb 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role: Executive Vice President and Chief Technology Officer
Signature: /s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege
Issuer symbol: MCRB
Transactions as of: 03 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 07 Feb 2023, 16:50:49 UTC
Previous filing: 31 Oct 2022
Next filing: 01 May 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MCRB	Restricted Stock Units	Award	$0	+47,500		$0.000000	47,500	03 Feb 2023	Common Stock	47,500		Direct	F1, F2
transaction	MCRB	Stock Option (Right to Buy)	Award	$0	+95,000		$0.000000	95,000	03 Feb 2023	Common Stock	95,000	$5.50	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2	The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter.
F3	The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.

Remarks:

Executive Vice President and Chief Technology Officer